title: α-1-Antitrypsin and IFN-γ reduce the severity of IC-mediated vasculitis by regulation of leukocyte recruitment in vivo.
abstract: IC-mediated vasculitis (ICV) can be life threatening. The cellular and immune mechanisms controlling ICV are poorly understood. Therefore, we investigated the role of α-1-antitrypsin (α1AT) and IFN-γ in reducing the severity of ICV in a mouse model in vivo. To induce ICV, mice were challenged with the reverse passive Arthus reaction (RPA), the prototypic in vivo model for leukocytoclastic vasculitis (LcV), and the modulation of vascular permeability, edema formation, and leukocyte recruitment was studied. To further analyze the dynamics of RPA, we applied intravital microscopy in the dorsal skinfold chamber. α1AT continuously led to reduced leukocyte recruitment. α1AT interfered with neutrophil recruitment through a KC-dependent mechanism and reduced KC-elicited neutrophil activation. In contrast to α1AT, IFN-γ-reduced leukocyte recruitment during RPA was clearly independent of KC. We also revealed that the recruitment of neutrophils during RPA was a prerequisite for full KC expression. Thus, therapeutic administration of α1AT and IFN-γ might be beneficial for limiting the duration and severity of ICV.
authors.affiliation: Department of Dermatology and Boltzmann Institute for Immunobiology of Skin, University of Münster, Münster, Germany. micha.feld@med.uni-duesseldorf.de
authors.forename: Micha
authors.initials: M
authors.lastname: Feld
authors.forename: Tobias
authors.initials: T
authors.lastname: Goerge
authors.forename: Carina
authors.initials: C
authors.lastname: Hillgruber
authors.forename: Annika Kathrin
authors.initials: AK
authors.lastname: Steingräber
authors.forename: Michaela
authors.initials: M
authors.lastname: Fastrich
authors.forename: Victoria
authors.initials: V
authors.lastname: Shpacovitch
authors.forename: Martin
authors.initials: M
authors.lastname: Steinhoff
mesh_terms: D000818:Animals; D001183:Arthus Reaction / Q000188:drug therapy; D002199:Capillary Permeability / Q000187:drug effects; D054360:Chemokine CXCL1 / Q000494:pharmacology; D004487:Edema / Q000188:drug therapy; D007371:Interferon-gamma / Q000008:administration & dosage*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009504:Neutrophils / Q000187:drug effects*; D011994:Recombinant Proteins / Q000008:administration & dosage*; D012720:Severity of Illness Index; D014361:Trypsin Inhibitors / Q000008:administration & dosage*; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000188:drug therapy*; D000515:alpha 1-Antitrypsin / Q000008:administration & dosage*
chemical_list: D054360:Chemokine CXCL1; C475895:Cxcl1 protein, mouse; D011994:Recombinant Proteins; D014361:Trypsin Inhibitors; D000515:alpha 1-Antitrypsin; D007371:Interferon-gamma